Avenda Health Brings AI Prostate Cancer Mapping to Arizona
Irvine, California, U.S., September 18, 2026 Avenda Health, an artificial intelligence-powered medical technology company focused on prostate cancer care,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Irvine, California, U.S., September 18, 2026 Avenda Health, an artificial intelligence-powered medical technology company focused on prostate cancer care,...
Salt Lake City, Utah, August 6, 2026 BlueWind Medical, Ltd. has received U.S. Food and Drug Administration (FDA) 510(k)...
DALLAS, July 27, 2026 CG Oncology, Inc. announced the publication of results from its pivotal Phase 3 BOND-003 Cohort...
PHILADELPHIA, July 16, 2026 Medicus Pharma announced that it has received written feedback from the U.S. Food and Drug...
PROVIDENCE, Rhode Island, USA, June 2, 2026 Signati Medical has achieved a significant regulatory milestone after receiving U.S. Food...
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
Hong Kong, China, May 25, 2026 Cornerstone Robotics (CSR) has announced that its Sentire® Endoscopic Surgical System has officially...
Hong Kong, China – May 25, 2026 Cornerstone Robotics (CSR) announced that its Sentire® Endoscopic Surgical System has officially...
WASHINGTON, May 14, 2026 Johnson & Johnson released findings from a groundbreaking global survey revealing the significant physical, emotional,...
DUBLIN, May 15, 2026 Keenova Therapeutics announced updated clinical findings on XIAFLEX® (collagenase clostridium histolyticum) for the treatment of...
